Cutler Group LP Prothena Corp Public LTD CO Put Options Transaction History

Cutler Group LP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2023 Jan 18, 2024	BUY	$32.31 - $52.32 $423,261 - $685,392	13,100 New	13,100 $26,000
Q4 2022 Feb 07, 2023	SELL	$52.05 - $65.0 $104,100 - $130,000	-2,000 Reduced 71.43%	800 $0
Q3 2022 Oct 25, 2022	BUY	$25.16 - $60.63 $70,448 - $169,764	2,800 New	2,800 $4,000
Q4 2018 Feb 05, 2019	SELL	$8.73 - $13.74 $362,295 - $570,210	-41,500 Closed	0 $0
Q3 2018 Nov 07, 2018	BUY	$12.7 - $15.79 $440,690 - $547,913	34,700 Added 510.29%	41,500 $54,000
Q2 2018 Aug 10, 2018	SELL	$10.99 - $44.21 $81,326 - $327,154	-7,400 Reduced 52.11%	6,800 $5,000
Q1 2018 May 11, 2018	BUY	$27.95 - $45.04 $47,515 - $76,568	1,700 Added 13.6%	14,200 $258,000
Q4 2017 Jan 17, 2018	BUY	$35.44 - $63.76 $92,144 - $165,776	2,600 Added 26.26%	12,500 $230,000
Q3 2017 Oct 17, 2017	BUY	$53.83 - $67.75 $532,917 - $670,725	9,900	9,900 $112,000

184

42.7M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $685M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.